ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1625

Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis

Alae Dhahbi1, Stephanie Ducharme-Benard2, Samer Hussein3, Rosalie-Sélène Meunier2, Hussein Baalbaki2, Carolyn Ross4 and Jean-Paul Makhzoum4, 1Laval University, Quebec, QC, Canada, 2Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 3Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Sherbrooke, Canada, 4Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada

Meeting: ACR Convergence 2024

Keywords: giant cell arteritis, Health Care, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Giant cell arteritis (GCA) is both a medical emergency and diagnostic challenge. Up to 45% of patients may require emergency department (ED) visits and/or hospitalization to expedite investigations. This leads to significant health care utilization and cost. This study aims to determine if a Fast-Track referral algorithm, combined with a non-invasive diagnostic tool, can reduce diagnostic delays, ED visits, hospitalizations, and visual loss associated with GCA.

Methods: A prospective study was conducted in our GCA Fast-Track (FT) clinic from June to September 2022. Patients referred to the FT clinic underwent an initial assessment and blood work performed within 24 hours of referral. A GCA expert evaluated the patients in the next 24-72 hours and performed a Color Doppler ultrasound (CDUS) of the temporal and axillary arteries. Consecutive patients with new-onset GCA confirmed through our FT clinic were included (FT group).

The control group was a retrospective cohort of patients with GCA (2003-2016) who had a temporal artery biopsy performed prior to the FT clinic implementation.

Collected information included the delay from 1) the first GCA symptom to glucocorticoids (GCs) initiation, 2) the first GCA symptom to the final diagnosis, and 3) the first medical contact to the final diagnosis. The occurrences of permanent vision loss, ED visits and hospitalizations (including their durations) were also recorded. Descriptive statistics for both the FT group and the control group were computed using R (version 4.2.1).

Results: A total of 109 patients with GCA were included: 21 patients in the FT group and 88 patients in the control group (Table 1). All patients with GCA met the ACR classification criteria for GCA (1990 or 2022 version).

The delay from GCA symptom onset to GCs was 25 days (interquartile range [IQR] 9 to 40 days) vs. 31 days (IQR 13 to 88 days) for the FT and control group, respectively (Table 2). The delay from GCA symptom onset to the final diagnosis of GCA was 21 days (IQR 8 to 56 days) in the FT group and 36 days (IQR 16 to 93 days) in the control group. The time elapsed from the first medical contact to the final diagnosis of GCA was 4 days (IQR 2 to 8 days) for the FT group and 7 days (IQR 3 to 12 days) for the control group.

ED visits occurred in 38.1% of patients in the FT group and 82.7% of patients in the control group. Hospitalization to investigate GCA occurred in 23.8% of patients of the FT group (median duration 3 days, IQR = 2 to 5 days) compared to 59.8% of patients in the control group (median duration 6 days, IQR = 3 to 9 days). The proportion of unilateral vision loss at diagnosis was 23.8% in the FT group and 19.3% in the control group (Table 3).

Conclusion: Implementing a GCA Fast-Track referral method with a bedside non-invasive diagnostic test such as CDUS can reduce health care utilization in GCA. The delay from the onset of GCA symptoms to first GCs was high in both groups and might explain the similar rates of vision loss at diagnosis. The effect of a GCA educational and awareness program in the general population to reduce incident vision loss should be investigated.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Dhahbi: None; S. Ducharme-Benard: None; S. Hussein: None; R. Meunier: None; H. Baalbaki: None; C. Ross: Otsuka, 6; J. Makhzoum: Abbvie, 5, Janssen, 6, Novartis, 5, Otsuka, 1, 6.

To cite this abstract in AMA style:

Dhahbi A, Ducharme-Benard S, Hussein S, Meunier R, Baalbaki H, Ross C, Makhzoum J. Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/impacts-of-a-fast-track-referral-clinic-on-health-care-utilization-delays-and-complications-in-patients-with-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impacts-of-a-fast-track-referral-clinic-on-health-care-utilization-delays-and-complications-in-patients-with-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology